Gregory L Moore

This inventor holds 84 USPTO granted patents and 55 published patent applications, plus 5 CIPO patents and 17 EPO patents, primarily in Heterodimeric Antibodies (CPC class C07K2317-31). Top assignees: Xencor, Inc., Amgen Inc.. Active years: 2009-2026.

USPTO Granted Patents = 84 (Patent Applications = 55)

% Patents Active = 97.6

CIPO Patents = 5 (Patent Applications = 13)

EPO Patents = 17 (Patent Applications = 38)

Average Co-Inventor Count = 4.5

ph-index = 13

Forward Citations = 604(Granted Patents)

Forward Citations (Not Self Cited) = 348(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Pasadena, CA (US) (2009 - 2015)
Azuza, CA (US) (2019 - 2022)
Monrovia, CA (US) (2009 - 2023)
Arcadia, CA (US) (2017 - 2023)
Asuza, CA (US) (2019 - 2023)
Azusa, CA (US) (2016 - 2024)

Company Filing History:

Years Active: 2009-2026

Loading Chart...

Areas of Expertise:

Heterodimeric Antibodies

Bispecific Antibodies

Fc Fusion Proteins

CD3 Binding

Tumor Antigens

IL-10 Proteins

Anti-CD28 Compositions

PD-1 Sequences

NKG2D Domains

Checkpoint Inhibitors

IgG1 Polypeptides

Somatostatin Receptor

84 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12703748 - Anti-CD28 compositions (2026-08-11),

2. 12617872 - HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS (2026-05-05),

3. 12497457 - METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES (2025-12-16),

4. 12466897 - HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS (2025-11-11),

5. 12448423 - Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domains (2025-10-21),

6. 12415849 - Heterodimeric proteins (2025-09-16),

7. 12378326 - Anti-CD28 x anti-PSMA antibodies (2025-08-05),

8. 12378313 - Bispecific binding agents binding to CLDN18.2 and CD3 (2025-08-05),

9. 12365743 - Anti-CD28 x anti-PSMA antibodies (2025-07-22),

10. 12359002 - Heterodimeric antibodies that bind CD3 and tumor antigens (2025-07-15),

11. 12152076 - Bispecific and monospecific antibodies using novel anti-PD-1 sequences (2024-11-26),

12. 12129309 - Heterodimeric antibodies that bind CD3 and CD38 (2024-10-29),

13. 12054545 - Heterodimeric antibodies that bind somatostatin receptor 2 (2024-08-06),

14. 12006345 - Untargeted and targeted IL-10 Fc-fusion proteins (2024-06-11),

15. 11945880 - Heterodimeric antibodies that bind CD3 and tumor antigens (2024-04-02),

Title: The Innovative Journey of Gregory L Moore

Introduction: Gregory L Moore, a talented inventor based in Pasadena, CA, has made significant contributions to the field of technology with his creative and groundbreaking ideas.

Latest Patents: Gregory L Moore holds several patents in various technological areas, including artificial intelligence, renewable energy, and medical devices. His most recent patent focuses on a revolutionary method for enhancing solar panel efficiency through advanced nanotechnology.

Career Highlights: Throughout his illustrious career, Gregory L Moore has worked with prestigious research institutions and leading tech companies to bring his inventions to life. His innovative solutions have not only improved existing technologies but have also paved the way for new advancements in the industry.

Collaborations: Gregory L Moore has collaborated with top engineers, scientists, and researchers to further develop his inventions. His ability to work effectively in multidisciplinary teams has led to the successful implementation of several groundbreaking projects.

Conclusion: Gregory L Moore's passion for innovation and his dedication to pushing the boundaries of technology have established him as a prominent figure in the world of inventors. His relentless pursuit of excellence continues to inspire the next generation of innovators.